Last 12 months
Inside the activity.
2 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2023 Filed Feb 24, 2023 22:47 UTC |
Duraibabu PrathyushaDirector
|
GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004886 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,624 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:47 UTC |
Quintero GilbertoDirector
|
GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004885 · form4.xml · nonDerivative · entry 1 Quintero Gilberto · CIK 0001927023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,650 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:47 UTC |
Korfin Michele IleneDirector
|
GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004884 · form4.xml · nonDerivative · entry 1 Korfin Michele Ilene · CIK 0001771664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,650 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 16:26 UTC |
Montecalvo Antonio S.VP Health Policy & Contracting
|
Tax withholdingClass A Common Stock | 717 | $2.75 | $1,971.75 |
DisclosureSEC source: 0001062993-23-004061 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,585 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 16:25 UTC |
Freedman LoriVP and General Counsel
|
Tax withholdingClass A Common Stock | 765 | $2.75 | $2,103.75 |
DisclosureSEC source: 0001062993-23-004059 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,445 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:24 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 799 | $2.75 | $2,197.25 |
DisclosureSEC source: 0001062993-23-004057 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,599 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:24 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 936 | $2.75 | $2,574.00 |
DisclosureSEC source: 0001062993-23-004056 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,627 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:24 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 953 | $2.75 | $2,620.75 |
DisclosureSEC source: 0001062993-23-004055 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,421 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:23 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 3,787 | $2.75 | $10,414.25 |
DisclosureSEC source: 0001062993-23-004054 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,988 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:26 UTC |
Montecalvo Antonio S.VP Health Policy & Contracting
|
Tax withholdingClass A Common Stock | 1,249 | $2.92 | $3,647.08 |
DisclosureSEC source: 0001062993-23-004061 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · VP Health Policy & Contracting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,302 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:25 UTC |
Freedman LoriVP and General Counsel
|
Tax withholdingClass A Common Stock | 3,635 | $2.92 | $10,614.20 |
DisclosureSEC source: 0001062993-23-004059 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,210 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:24 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 3,346 | $2.92 | $9,770.32 |
DisclosureSEC source: 0001062993-23-004057 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,398 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:24 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 4,599 | $2.92 | $13,429.08 |
DisclosureSEC source: 0001062993-23-004056 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,563 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:24 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 3,506 | $2.92 | $10,237.52 |
DisclosureSEC source: 0001062993-23-004055 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,374 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:23 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 21,517 | $2.92 | $62,829.64 |
DisclosureSEC source: 0001062993-23-004054 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,775 Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 20:29 UTC |
KATZ MICHAEL W10% owner
|
PurchaseClass A Common Stock | 3,000 | $2.56 | $7,680.00 |
DisclosureSEC source: 0001062993-22-022671 · form4.xml · nonDerivative · entry 2 KATZ MICHAEL W · CIK 0001279930 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,382 Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 20:29 UTC |
KATZ MICHAEL W10% owner
|
PurchaseClass A Common Stock | 3,000 | $2.57 | $7,710.00 |
DisclosureSEC source: 0001062993-22-022671 · form4.xml · nonDerivative · entry 1 KATZ MICHAEL W · CIK 0001279930 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,382 Read SEC document |
| August 20, 2022 Filed Aug 24, 2022 21:56 UTC |
Grow BrianChief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 805 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001062993-22-018718 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 805 shares Expires 2022-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 20, 2022 Filed Aug 24, 2022 21:56 UTC |
Grow BrianChief Commercial Officer
|
Exercise / conversionClass A Common Stock | 805 | $1.46 | $1,175.30 |
DisclosureSEC source: 0001062993-22-018718 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 18:37 UTC |
Driscoll Michael JosephDirector
|
PurchaseClass A Common Stock | 5,000 | $4.80 | $24,000.00 |
DisclosureSEC source: 0001062993-22-018041 · form4.xml · nonDerivative · entry 1 Driscoll Michael Joseph · CIK 0001912097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,547 Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 18:43 UTC |
Leibowitz Arthur SDirector
|
PurchaseClass A Common Stock | 3,000 | $4.76 | $14,265.00 |
DisclosureSEC source: 0001062993-22-018040 · form4.xml · nonDerivative · entry 1 Leibowitz Arthur S · CIK 0001467329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,854 Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 21:03 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 505,050 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-015767 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 505,050 shares Expires 2023-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 21:03 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionClass A Common Stock | 505,050 | $0.99 | $499,999.50 |
DisclosureSEC source: 0001062993-22-015767 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2022 Filed Jun 13, 2022 17:44 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 29,669 | $4.89 | $145,081.41 |
DisclosureSEC source: 0001062993-22-014816 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,248,027 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.83 to $4.95, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 13, 2022 Filed Jun 13, 2022 17:43 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 29,669 | $4.89 | $145,081.41 |
DisclosureSEC source: 0001062993-22-014814 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,248,027 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.83 to $4.95, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:44 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 331 | $5.30 | $1,754.30 |
DisclosureSEC source: 0001062993-22-014816 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,277,696 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.31, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:43 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 331 | $5.30 | $1,754.30 |
DisclosureSEC source: 0001062993-22-014814 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,277,696 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.31, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 19:13 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 20,000 | $5.39 | $107,800.00 |
DisclosureSEC source: 0001062993-22-014508 · form4.xml · nonDerivative · entry 3 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,278,027 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.34 to $5.49, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 19:11 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 20,000 | $5.39 | $107,800.00 |
DisclosureSEC source: 0001062993-22-014506 · form4.xml · nonDerivative · entry 3 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,278,027 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.34 to $5.49, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 19:13 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 50,000 | $5.49 | $274,500.00 |
DisclosureSEC source: 0001062993-22-014508 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,298,027 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 19:11 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 50,000 | $5.49 | $274,500.00 |
DisclosureSEC source: 0001062993-22-014506 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,298,027 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 19:13 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Erani Dennis10% owner
|
SaleClass A Common Stock | 100,000 | $5.41 | $541,000.00 |
DisclosureSEC source: 0001062993-22-014508 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,348,027 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.55, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 19:11 UTC |
ERANI ALBERT10% owner
NUSSDORF GLENN HDirector · 10% owner
Ades Alan A.Director · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
Alan Ades 2014 GRAT10% owner
Wisdom Starr10% owner
|
SaleClass A Common Stock | 100,000 | $5.41 | $541,000.00 |
DisclosureSEC source: 0001062993-22-014506 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,348,027 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.55, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares being sold pursuant to this Form 4. None of the other members of the Group has a pecuniary interest in the shares being sold pursuant to this Form 4. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 36,239 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 36,239 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 36,239 | $5.53 | $200,401.67 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.62, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionClass A Common Stock | 36,239 | $0.99 | $35,876.61 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 116,608 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · derivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,239 Underlying: Class A Common Stock · 116,608 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 116,608 | $5.58 | $650,672.64 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.73, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionClass A Common Stock | 116,608 | $0.99 | $115,441.92 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 94,487 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · derivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,847 Underlying: Class A Common Stock · 94,487 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 94,487 | $5.52 | $521,568.24 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $5.66, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:51 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionClass A Common Stock | 94,487 | $0.99 | $93,542.13 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 109,240 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,334 Underlying: Class A Common Stock · 109,240 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 31, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 109,240 | $5.68 | $620,483.20 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.58 to $5.89, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| May 31, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionClass A Common Stock | 109,240 | $0.99 | $108,147.60 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 56,362 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · derivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,574 Underlying: Class A Common Stock · 56,362 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 27, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 56,362 | $5.93 | $334,226.66 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $5.98, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| May 27, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionClass A Common Stock | 56,362 | $0.99 | $55,798.38 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 61,202 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · derivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,936 Underlying: Class A Common Stock · 61,202 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:16 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 61,202 | $5.71 | $349,463.42 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.55 to $5.875, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.